Globus Medical, Inc.

Globus Medical, Inc.

GMED
Globus Medical, Inc.US flagNew York Stock Exchange
78.29
USD
+0.17
- -
10.56BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.69
5.03
5.73
5.9
6.61
7.28
7.92
8
9.51
10.18
13.87
18.56
21.74
23.32
Basic EPS, GAAP
0.74
0.98
1.19
1.09
1.12
1.6
1.57
1.04
1.48
1.89
1.09
0.76
3.98
3.97
Free Cash Flow per Basic Share
0.75
0.58
0.77
1.12
1.12
1.25
1.02
1.37
2.18
1.04
1.46
2.99
4.28
5.57
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.06
6.18
7.5
8.67
10.01
12.03
14.05
15.11
17.15
18.43
29.32
30.4
40.61
35.43
Tangible Book Value per Share
4.54
5.26
6.19
6.93
7.92
9.89
11.97
12.66
14.7
15.82
12.02
14.19
21.25
19.6
Basic Weighted Avg Shares
93
94
95
96
96
98
99
99
101
100
113
136
135
135
Sales/Revenue/Turnover
434
474
545
564
636
713
785
789
958
1,023
1,568
2,519
2,939
3,145
Operating Margin (%)
28.71
30.16
30.16
28.21
26.12
24.81
22.51
14.63
20.34
23.1
12.84
8.71
18.28
21.42
Depreciation Expense
19
22
24
39
42
42
53
63
70
68
146
253
277
280
Net Income, GAAP
69
92
113
104
107
156
155
102
149
190
123
103
538
535
Effective Tax Rate (%)
32.73
33.29
34.73
33.66
36.83
17.04
18.29
18.76
17.3
21.75
25.71
14.69
11.11
18.89
Profit Margin (%)
15.79
19.5
20.7
18.5
16.88
21.95
19.76
12.96
15.57
18.59
7.83
4.09
18.3
17.03
Working Capital
349
381
462
434
527
535
576
701
724
824
1,523
1,321
1,627
1,736
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
508
84
104
97
Total Equity
472
585
715
832
968
1,186
1,402
1,506
1,741
1,846
3,998
4,177
4,573
4,769
Return on Invested Capital (%)
19.45
17.92
16.38
13.55
11.59
13.59
11.16
6.45
9.91
10.26
4.68
4.03
10.12
11.75
Return on Capital (%)
15.9
17.38
17.21
13.22
11.46
13.51
10.9
7.03
9.19
10.58
3.86
2.23
11.44
11.52
Return on Common Equity (%)
15.98
17.49
17.34
13.49
11.93
14.53
11.99
7.03
9.19
10.6
4.2
2.52
12.29
11.81

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
15
15
14
LT Borrowings
- -
- -
- -
LT Finance Leases
104
100
97
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
113
136
135
Market Capitalization
9,833
11,689
10,635

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,126
2,198
2,216
Cash, Cash Equivalents & STI
557
630
595
Accounts Receivable, Net
679
686
692
Inventories
759
773
811
Total Current Liabilities
498
482
479
Payables & Accruals
269
274
275
ST Debt
15
15
14
Deferred Revenue
28
26
28

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.3%
30.43%
9.48%
Free Cash Flow
33.27%
51.26%
42.89%
Net Income, GAAP
45.03%
88.81%
422.28%
Sales/Revenue/Turnover
19.78%
31.76%
16.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
607
630
626
657
2,519
2025
598
745
769
826
2,939
2026
760
790
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
0.23
0.38
0.19
0.76
2025
0.55
1.5
0.88
1.05
3.98
2026
0.92
1.12
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Keith W. Pfeil
Full Time Employees
6,000
Sector
Healthcare
Industry
Medical - Devices
Address
2560 General Armistead Avenue Audubon PA United States of America 19403-5214
IPO Date
Aug 3, 2012
Business
Globus Medical, Inc. is a leading musculoskeletal solutions company specializing in the design, development, manufacturing, and commercialization of a broad portfolio of products for the spine, orthopedic trauma, and neuromodulation markets. Its core product offerings include spinal implants and biologics; orthopedic trauma fixation devices such as plates, nails, and screws; joint reconstruction products including hip and knee systems; enabling technologies like surgical navigation and robotics; and high-frequency neuromodulation devices for chronic pain management. The company operates extensively across the United States and has an expanding international presence, serving hospitals, ambulatory surgery centers, and healthcare providers. Founded in 2003, Globus Medical is headquartered in Audubon, Pennsylvania. Recent major developments include the strategic acquisition of Nevro Corporation in early 2025, which significantly broadened Globus Medical's neuromodulation portfolio with advanced high-frequency spinal cord stimulation technology, positioning the company to access a $2.5 billion market opportunity. The company also continues to expand its orthopedic trauma product line with several new FDA-cleared systems in 2024 and 2025, including the TENSOR Suture Button System, ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments, and CAPTIVATE SOLA Headless Screws. Additionally, Globus Medical launched innovative anterior lumbar interbody fusion products such as the COHERE ALIF Spacer and Modulus ALIF Blades in 2025, enhancing its spine surgery portfolio. The company is undergoing integration of recent acquisitions including NuVasive to realize operational synergies while focusing on organic innovation, enhanced surgeon engagement, and scaling its hip and knee business. Globus Medical's industry segments encompass spinal surgery, orthopedic trauma, joint reconstruction, enabling surgical technologies, and neuromodulation. The company targets orthopedic surgeons, neurosurgeons, and healthcare institutions. Its growth strategy emphasizes organic product innovation combined with selective acquisitions and operational efficiency improvements under new leadership following a CEO transition in 2025. Globus Medical remains committed to advancing patient outcomes through superior engineering and a comprehensive range of musculoskeletal solutions.

Company News

  • Globus Medical Announces CE Mark for Excelsius3D™ Imaging System

  • 3 Reasons Growth Investors Will Love Globus Medical (GMED)

  • Wall Street Analysts Believe Globus Medical (GMED) Could Rally 25.03%: Here's is How to Trade

  • GMED or ITGR: Which Is the Better Value Stock Right Now?

  • Globus Medical (GMED) is a Top-Ranked Momentum Stock: Should You Buy?

  • American Capital Management Inc. Takes Position in Globus Medical, Inc. $GMED

  • Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions

  • Here's Why Globus Medical (GMED) is a Strong Value Stock

  • 4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026

  • Globus Medical: 7 Quarters Of Margin Expansion, Priced For None

  • Here is Why Growth Investors Should Buy Globus Medical (GMED) Now

  • Globus Medical (GMED) Upgraded to Strong Buy: Here's Why

  • GMED vs. ITGR: Which Stock Is the Better Value Option?

  • Globus Medical Q2 Earnings Call Highlights

  • GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution

  • Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

  • Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript

  • Globus Medical Reports Second Quarter 2026 Results

  • Why Globus Medical (GMED) is a Top Value Stock for the Long-Term

  • Globus Medical, Inc. $GMED Shares Purchased by Amundi